Valuation: Novartis

Market Cap 269B 234B 221B 201B 377B 25,753B 377B 2,644B 1,019B 13,119B 1,010B 987B 42,333B P/E 2026 *
20x
P/E 2027 * 16.8x
Enterprise Value 300B 262B 247B 225B 421B 28,779B 422B 2,954B 1,139B 14,660B 1,128B 1,103B 47,306B EV / Sales 2026 *
5.21x
EV / Sales 2027 * 4.84x
Free-Float
91.66%
Yield 2026 *
3.08%
Yield 2027 * 3.21%
Manager TitleAgeSince
Chief Executive Officer 50 31/01/2018
Director of Finance/CFO - 15/03/2026
Compliance Officer 58 13/04/2025
Director TitleAgeSince
Director/Board Member 67 31/12/2014
Director/Board Member 69 31/12/2015
Director/Board Member 61 31/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.58% - - 269B
-1.39%+2.34%+54.91%+111.75% 1,038B
-1.19%+1.18%+52.94%+66.69% 649B
-0.39%+1.04%+18.88%+72.38% 467B
-1.26%+0.47%+33.64%+45.27% 355B
-0.57%+2.28%+18.45%+26.65% 269B
-0.22%+4.19%+9.77%+14.29% 260B
+2.74%+3.06%+37.75%+45.93% 213B
-0.72%-6.29%-32.53%-59.69% 176B
-0.27%+2.83%+31.97%+100.03% 187B
Average -0.26%+1.04%+25.09%+47.03% 401.68B
Weighted average by Cap. -0.58%+1.47%+35.39%+65.84%

Financials

2026 *2027 *
Net sales 57.65B 50.27B 47.34B 43.11B 80.84B 5,523B 80.94B 567B 219B 2,814B 217B 212B 9,079B 61.33B 53.47B 50.36B 45.86B 85.99B 5,875B 86.1B 603B 232B 2,993B 230B 225B 9,658B
Net income 14.2B 12.38B 11.66B 10.62B 19.9B 1,360B 19.93B 140B 53.81B 693B 53.32B 52.14B 2,236B 15.75B 13.74B 12.94B 11.78B 22.09B 1,509B 22.12B 155B 59.71B 769B 59.17B 57.86B 2,481B
Net Debt 31.58B 27.53B 25.93B 23.62B 44.28B 3,025B 44.33B 311B 120B 1,541B 119B 116B 4,973B 27.89B 24.31B 22.9B 20.85B 39.1B 2,671B 39.15B 274B 106B 1,361B 105B 102B 4,391B
Logo Novartis
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!